Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO

PloS One
Mitchell B DiccianniLinda S Sorkin

Abstract

Anti-GD2 therapy with dinutuximab is effective in improving the survival of high-risk neuroblastoma patients in remission and after relapse. However, allodynia is the major dose-limiting side effect, hindering its use for neuroblastoma patients at higher doses and for other GD2-expressing malignancies. As polyamines can enhance neuronal sensitization, including development of allodynia and other forms of pathological pain, we hypothesized that polyamine depletion might prove an effective strategy for relief of anti-GD2 induced allodynia. Sprague-Dawley rats were allowed to drink water containing various concentrations of difluoromethylornithine (DFMO) for several days prior to behavioral testing. Anti-GD2 (14G2a) was injected into the tail vein of lightly sedated animals and basal mechanical hindpaw withdrawal threshold assessed by von Frey filaments. Endpoint serum DFMO and polyamines, assessed 24h after 14G2a injection, were measured by HPLC and mass spectrometry. An i.v. injection of 14G2a causes increased paw sensitivity to light touch in this model, a response that closely mimics patient allodynia. Animals allowed to drink water containing 1% DFMO exhibited a significant reduction of 14G2a-induced pain sensitivity (allodyn...Continue Reading

References

Jul 1, 1995·Cancer Immunology, Immunotherapy : CII·M M Uttenreuther-FischerA L Yu
Jul 1, 1994·Journal of Neuroscience Methods·S R ChaplanT L Yaksh
Apr 16, 2004·Journal of Neurobiology·Kristen L BoeshoreRichard E Zigmond
Aug 4, 2004·Amino Acids·H M Wallace, A V Fraser
Sep 29, 2007·Pain·Cyril RivatGuy Simonnet
Feb 13, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Anne R SimoneauFrank L Meyskens
Jan 29, 2010·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Bernard G CipollaJacques-Philippe Moulinoux
Oct 1, 2010·The New England Journal of Medicine·Alice L YuUNKNOWN Children's Oncology Group
Feb 5, 2011·Nephron. Clinical Practice·Marlies NoordzijKitty J Jager
May 17, 2011·Biochemical Pharmacology·Mariane A SilvaJuliano Ferreira
Jul 19, 2011·Pharmacology, Biochemistry, and Behavior·Camila GewehrJuliano Ferreira
Dec 5, 2013·Pain Research and Treatment·Guillermo M AlexanderRobert J Schwartzman
Jan 22, 2015·Expert Opinion on Therapeutic Targets·Maya Suzuki, Nai-Kong V Cheung
May 27, 2015·Cancers·Noothan Jyothi Satheesh, Dietrich Büsselberg
Mar 26, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas F EvageliouMichael D Hogarty
Apr 14, 2016·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Yan LinJicheng Liu
Sep 29, 2018·Scientific Reports·Giselle L Saulnier ShollerJacqueline M Kraveka

❮ Previous
Next ❯

Citations

Jan 29, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alice L YuPaul M Sondel

❮ Previous
Next ❯

Software Mentioned

OriginPro
ARRIVE
Graphpad Prism

Related Concepts

Related Feeds

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
J A O'ShaughnessyAndrea Manni
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
J GelmanB Klitzman
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience
T A SlotkinJ V Bartolome
© 2021 Meta ULC. All rights reserved